Compare Lam Research Corporation (LRCX) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lam Research Corporation vs Natera Inc. Common Stock — how do they compare? Lam Research Corporation trades at $278.37 (market cap $376.82B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Lam Research Corporation is far larger — about 6.6× Natera Inc. Common Stock's market cap, and Lam Research Corporation pays a 0.44% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lam Research Corporation for 61 Days and Natera Inc. Common Stock for 0 Days on average.
| LRCX | NTRA | |
|---|---|---|
Market Cap | $376.82B | $57.03B |
Volume | 8,149,593 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $433.33 | $425.64 |
52-Week Low | $139.59 | $179.42 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | $374.97B | $56.18B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $286.92, down 7.31% in the last session, amid a bearish technical signal. The stock shows strong fundamentals with revenue growth to $18.44B in 2025 and a 31.27% net income margin. Recent quarters have consistently beaten EPS estimates, with Q3 2026 expected at $2.18. Analyst consensus remains strongly bullish with a $375.68 price target, though technical indicators suggest near-term pressure with support at $300.
Outlook: LRCX is positioned to benefit from AI-driven semiconductor equipment demand, with projected revenue growth to $23.2B in 2026. Risks include cyclical industry volatility and execution challenges. The current valuation (P/E 52.28) is high but supported by robust profitability and growth prospects. Institutional sentiment is positive with 78% buy ratings.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
